Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Spinal Diseases: HELP
Articles by Catherine H. Smith
Based on 6 articles published since 2009
(Why 6 articles?)

Between 2009 and 2019, C. H. Smith wrote the following 6 articles about Spinal Diseases.
+ Citations + Abstracts
1 Guideline Psoriasis: guidance on assessment and referral. 2014

Samarasekera, Eleanor J / Smith, Catherine H / Anonymous1571028 / Anonymous1581028. ·National Clinical Guideline Centre, Royal College of Physicians of London. ·Clin Med (Lond) · Pubmed #24715130.

ABSTRACT: This concise guideline summarises the key recommendations from the recent National Institute for Health and Care Excellence (NICE) clinical guideline on the assessment and management of psoriasis (CG153) that are relevant to the non-dermatologist. The aim is to highlight important considerations for assessment and referral of people with psoriasis, including identification of relevant comorbid conditions. Psoriasis is a common inflammatory skin condition and, especially when severe, can be associated with increased risk of cardiovascular disease, diabetes and depression. Functional, psychological and social morbidity can also be encountered, and the extent of the disability is frequently underestimated. Importantly, highly effective treatments are available. Appropriate assessment and referral of people with psoriasis therefore has the potential to improve outcomes by correctly identifying the appropriate treatment pathway. Assessment should involve not only disease severity but also the impact on patient well-being and whether the patient has any comorbid conditions, such as psoriatic arthritis, which requires rapid referral to a rheumatologist.

2 Guideline The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. 2013

Coates, Laura C / Tillett, William / Chandler, David / Helliwell, Philip S / Korendowych, Eleanor / Kyle, Stuart / McInnes, Iain B / Oliver, Susan / Ormerod, Anthony / Smith, Catherine / Symmons, Deborah / Waldron, Nicola / McHugh, Neil J / Anonymous440765. ·Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath BA1 1RL, UK. neil.mchugh@rnhrd.nhs.uk. ·Rheumatology (Oxford) · Pubmed #23887065.

ABSTRACT: -- No abstract --

3 Article Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort. 2017

Tillett, William / Charlton, Rachel / Nightingale, Alison / Snowball, Julia / Green, Amelia / Smith, Catherine / Shaddick, Gavin / McHugh, Neil. ·Department of Rheumatology, Royal National Hospital for Rheumatic Diseases. · Department of Pharmacy and Pharmacology. · Department of Mathematical Sciences, University of Bath, Bath. · St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London. · Department of Mathematics, University of Exeter, Exeter, UK. ·Rheumatology (Oxford) · Pubmed #28968790.

ABSTRACT: Objectives: To describe the time interval between the onset of psoriasis and PsA in the UK primary care setting and compare with a large, well-classified secondary care cohort. Methods: Patients with PsA and/or psoriasis were identified in the UK Clinical Practice Research Datalink (CPRD). The secondary care cohort comprised patients from the Bath PsA longitudinal observational cohort study. For incident PsA patients in the CPRD who also had a record of psoriasis, the time interval between PsA diagnosis and first psoriasis record was calculated. Comparisons were made with the time interval between diagnoses in the Bath cohort. Results: There were 5272 eligible PsA patients in the CPRD and 815 in the Bath cohort. In both cohorts, the majority of patients (82.3 and 61.3%, respectively) had psoriasis before their PsA diagnosis or within the same calendar year (10.5 and 23.8%), with only a minority receiving their PsA diagnosis first (7.1 and 14.8%). Excluding those who presented with arthritis before psoriasis, the median time between diagnoses was 8 years [interquartile range (IQR) 2-15] in the CPRD and 7 years (IQR 0-20) in the Bath cohort. In the CPRD, 60.1 and 75.1% received their PsA diagnosis within 10 and 15 years of their psoriasis diagnosis, respectively; this was comparable with 57.2 and 67.7% in the Bath cohort. Conclusion: A similar distribution for the time interval between psoriasis and arthritis was observed in the CPRD and secondary care cohort. These data can inform screening strategies and support the validity of data from each cohort.

4 Article Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis. 2017

Bowes, John / Ashcroft, James / Dand, Nick / Jalali-Najafabadi, Farideh / Bellou, Eftychia / Ho, Pauline / Marzo-Ortega, Helena / Helliwell, Philip S / Feletar, Marie / Ryan, Anthony W / Kane, David J / Korendowych, Eleanor / Simpson, Michael A / Packham, Jonathan / McManus, Ross / Brown, Matthew A / Smith, Catherine H / Barker, Jonathan N / McHugh, Neil / FitzGerald, Oliver / Warren, Richard B / Barton, Anne. ·Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK. · Division of Genetics and Molecular Medicine, King's College London, Guy's Hospital, London, UK. · NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, UK. · NIHR Leeds Musculoskeletal 12 Biomedical Research Unit, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, UK. · Department of Rheumatology, Emeritus Research, Melbourne, Victoria, Australia. · Department of Clinical Medicine, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland. · Adelaide and Meath Hospital and Trinity College Dublin, Dublin, Ireland. · Royal National Hospital for Rheumatic Diseases and Department Pharmacy and Pharmacology, University of Bath, Bath, UK. · Department of Rheumatology, St Vincent's University Hospital, UCD School of Medicine and Medical Sciences and Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland. · Haywood Academic Rheumatology Centre, Institute of Applied Clinical Science, Keele University, Stoke on Trent, UK. · Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia. · St John's Institute of Dermatology, Guys and St Thomas' Foundation Trust, London, UK. · St John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London, London, UK. · Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester, UK. ·Ann Rheum Dis · Pubmed #28821532.

ABSTRACT: OBJECTIVES: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis, with a strong heritable component, affecting patients with psoriasis. Here we attempt to identify genetic variants within the major histocompatibility complex (MHC) that differentiate patients with PsA from patients with cutaneous psoriasis alone (PsC). METHODS: 2808 patients with PsC, 1945 patients with PsA and 8920 population controls were genotyped. We imputed SNPs, amino acids and classical HLA alleles across the MHC and tested for association with PsA compared to population controls and the PsC patient group. In addition we investigated the impact of the age of disease onset on associations. RESULTS: HLA-C*06:02 was protective of PsA compared to PsC (p=9.57×10 CONCLUSIONS: By controlling for the age of psoriasis onset, we show, for the first time, that

5 Article Development and testing of new candidate psoriatic arthritis screening questionnaires combining optimal questions from existing tools. 2014

Coates, Laura C / Walsh, Jessica / Haroon, Muhammad / FitzGerald, Oliver / Aslam, Tariq / Al Balushi, Farida / Burden, A D / Burden-Teh, Esther / Caperon, Anna R / Cerio, Rino / Chattopadhyay, Chandrabhusan / Chinoy, Hector / Goodfield, Mark J D / Kay, Lesley / Kelly, Stephen / Kirkham, Bruce W / Lovell, Christopher R / Marzo-Ortega, Helena / McHugh, Neil / Murphy, Ruth / Reynolds, Nick J / Smith, Catherine H / Stewart, Elizabeth J C / Warren, Richard B / Waxman, Robin / Wilson, Hilary E / Helliwell, Philip S. ·Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, UK. ·Arthritis Care Res (Hoboken) · Pubmed #24470406.

ABSTRACT: OBJECTIVE: Several questionnaires have been developed to screen for psoriatic arthritis (PsA), but head-to-head studies have found limitations. This study aimed to develop new questionnaires encompassing the most discriminative questions from existing instruments. METHODS: Data from the CONTEST study, a head-to-head comparison of 3 existing questionnaires, were used to identify items with a Youden index score of ≥0.1. These were combined using 4 approaches: CONTEST (simple additions of questions), CONTESTw (weighting using logistic regression), CONTESTjt (addition of a joint manikin), and CONTESTtree (additional questions identified by classification and regression tree [CART] analysis). These candidate questionnaires were tested in independent data sets. RESULTS: Twelve individual questions with a Youden index score of ≥0.1 were identified, but 4 of these were excluded due to duplication and redundancy. Weighting for 2 of these questions was included in CONTESTw. Receiver operating characteristic (ROC) curve analysis showed that involvement in 6 joint areas on the manikin was predictive of PsA for inclusion in CONTESTjt. CART analysis identified a further 5 questions for inclusion in CONTESTtree. CONTESTtree was not significant on ROC curve analysis and discarded. The other 3 questionnaires were significant in all data sets, although CONTESTw was slightly inferior to the others in the validation data sets. Potential cut points for referral were also discussed. CONCLUSION: Of 4 candidate questionnaires combining existing discriminatory items to identify PsA in people with psoriasis, 3 were found to be significant on ROC curve analysis. Testing in independent data sets identified 2 questionnaires (CONTEST and CONTESTjt) that should be pursued for further prospective testing.

6 Article Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). 2013

Coates, L C / Aslam, T / Al Balushi, F / Burden, A D / Burden-Teh, Esther / Caperon, A R / Cerio, R / Chattopadhyay, C / Chinoy, H / Goodfield, M J D / Kay, L / Kelly, S / Kirkham, B W / Lovell, C R / Marzo-Ortega, H / McHugh, N / Murphy, R / Reynolds, N J / Smith, C H / Stewart, E J C / Warren, R B / Waxman, R / Wilson, H E / Helliwell, P S. ·LIMM Division of Rheumatic and Musculoskeletal Disease and NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, UK. ·Br J Dermatol · Pubmed #23311587.

ABSTRACT: BACKGROUND: Multiple questionnaires to screen for psoriatic arthritis (PsA) have been developed but the optimal screening questionnaire is unknown. OBJECTIVES: To compare three PsA screening questionnaires in a head-to-head study using CASPAR (the Classification Criteria for Psoriatic Arthritis) as the gold standard. METHODS: This study recruited from 10 U.K. secondary care dermatology clinics. Patients with a diagnosis of psoriasis, not previously diagnosed with PsA, were given all three questionnaires. All patients who were positive on any questionnaire were invited for a rheumatological assessment. Receiver operating characteristic (ROC) curves were used to compare the sensitivity, specificity and area under the curve of the three questionnaires according to CASPAR criteria. RESULTS: In total, 938 patients with psoriasis were invited to participate and 657 (70%) patients returned the questionnaires. One or more questionnaires were positive in 314 patients (48%) and 195 (62%) of these patients attended for assessment. Of these, 47 patients (24%) were diagnosed with PsA according to the CASPAR criteria. The proportion of patients with PsA increased with the number of positive questionnaires (one questionnaire, 19·1%; two, 34·0%; three, 46·8%). Sensitivities and specificities for the three questionnaires, and areas under the ROC curve were, respectively: Psoriatic Arthritis Screening Evaluation (PASE), 74·5%, 38·5%, 0·594; Psoriasis Epidemiology Screening Tool (PEST), 76·6%, 37·2%, 0·610; Toronto Psoriatic Arthritis Screen (ToPAS), 76·6%, 29·7%, 0·554. The majority of patients with a false positive response had degenerative or osteoarthritis. CONCLUSION: Although the PEST and ToPAS questionnaires performed slightly better than the PASE questionnaire at identifying PsA, there is little difference between these instruments. These screening tools identify many cases of musculoskeletal disease other than PsA.